Monoclonal Antibodies
Pertuzumab + Trastuzumab + Chemotherapy for Advanced Breast Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial is testing pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation to see how well it works in treating HER2-positive stage II-IV breast cancer.
ST-067-001 for Solid Tumors
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing a new drug called ST-067 on patients with certain types of cancer that have not responded to previous treatments. The goal is to find the safest and most effective dose and to see how well it works against these cancers.
Procedure
Lymphovenous Bypass Procedure for Breast Cancer
Recruiting2 awards4 criteria
Houston, Texas
This trial studies whether a surgical procedure called lymphovenous bypass can prevent arm swelling in patients with certain types of breast cancer or melanoma. The surgery creates a new path for fluid to move away from the arms, which may help stop swelling before it starts. Lymphovenous bypass is a surgical procedure that has been used to treat lymphedema by creating a new pathway for lymphatic fluid to drain, potentially reducing swelling.
Popular Filters
Trials for Breast Cancer Patients
Monoclonal Antibodies
Combination Therapy for Inflammatory Breast Cancer
Recruiting3 awardsPhase 2
Houston, Texas
This trial is studying a combination of immunotherapy, targeted therapy, and chemotherapy to see if it is more effective than standard chemotherapy in treating patients with metastatic inflammatory breast cancer.
Chemotherapy
Cancer Vaccine + GM-CSF and Cyclophosphamide for Triple Negative Breast Cancer
Recruiting0 awardsPhase 2
Scottsdale, Arizona
This trial tests a combination of a special vaccine, an immune booster, and a chemotherapy drug to prevent the return of triple negative breast cancer. It aims to help the immune system fight off cancer cells and use chemotherapy to kill any remaining ones.
Checkpoint Inhibitor
Pembrolizumab for Breast Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial looks at how well pembrolizumab works for treating patients with hormone receptor positive inflammatory breast cancer who are receiving hormone therapy and didn't achieve a pathological complete response to chemotherapy.
Trials for LABC Patients
Monoclonal Antibodies
Combination Therapy for Inflammatory Breast Cancer
Recruiting3 awardsPhase 2
Houston, Texas
This trial is studying a combination of immunotherapy, targeted therapy, and chemotherapy to see if it is more effective than standard chemotherapy in treating patients with metastatic inflammatory breast cancer.
Chemotherapy
Cancer Vaccine + GM-CSF and Cyclophosphamide for Triple Negative Breast Cancer
Recruiting0 awardsPhase 2
Scottsdale, Arizona
This trial tests a combination of a special vaccine, an immune booster, and a chemotherapy drug to prevent the return of triple negative breast cancer. It aims to help the immune system fight off cancer cells and use chemotherapy to kill any remaining ones.
Checkpoint Inhibitor
Pembrolizumab for Breast Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial looks at how well pembrolizumab works for treating patients with hormone receptor positive inflammatory breast cancer who are receiving hormone therapy and didn't achieve a pathological complete response to chemotherapy.
Trials With No Placebo
Monoclonal Antibodies
Combination Therapy for Inflammatory Breast Cancer
Recruiting3 awardsPhase 2
Houston, Texas
This trial is studying a combination of immunotherapy, targeted therapy, and chemotherapy to see if it is more effective than standard chemotherapy in treating patients with metastatic inflammatory breast cancer.
Checkpoint Inhibitor
Pembrolizumab for Breast Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial looks at how well pembrolizumab works for treating patients with hormone receptor positive inflammatory breast cancer who are receiving hormone therapy and didn't achieve a pathological complete response to chemotherapy.
Taxane
Ruxolitinib + Chemotherapy for Breast Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing a new drug called Ruxolitinib combined with three other cancer drugs to treat Inflammatory Breast Cancer (IBC). It targets patients who may not respond well to typical treatments. Ruxolitinib works by blocking a pathway that cancer cells need to grow and helps other drugs be more effective. Ruxolitinib has been beneficial in the treatment of myelofibrosis.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.